Prospective, Multicenter Study Supported by the French National Institute of Cancer Also Demonstrates that Treatment with the TomoTherapy Platform Resulted in a Significantly Better Cancer-Specific Survival Rate and Post-Treatment Salivary Function SUNNYVALE, Calif.
Transactions Facilitate Reduction of Short-term Debt and Potential Dilution to Shareholders SUNNYVALE, Calif. , July 28, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) has entered into privately negotiated agreements with a limited number of existing holders of the company's outstanding
iDMS System Allows Seamless Integration between Accuray Radixact™, TomoTherapy® and CyberKnife® Systems and Treatment Planning Systems SUNNYVALE, Calif. , July 31, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today it has received 510(k) clearance from the U.S.
SUNNYVALE, Calif. , Aug. 4, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the first studies validating the benefits of the leading-edge Radixact™ System were presented at the 59th Annual Meeting of the American Association of Physicists in Medicine (AAPM) held in
SUNNYVALE, Calif. , Aug. 14, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its fourth quarter and fiscal year 2017 ended June 30, 2017 on Tuesday, August 22, 2017 after the market close. Management will host a conference call to review the results at 1:30 p.m.
Freestanding Center is First in the Western U.S. to Treat Patients with this "Smart" Radiation Therapy Delivery System with Fully-Integrated Treatment Planning and Data Management Systems SUNNYVALE, Calif. , Aug. 17, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and the Summit Cancer
SUNNYVALE, Calif. , Aug. 22, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2017 . Q4 Fiscal 2017 and Recent Highlights Gross orders of $85.7 million driven by strong demand from both the new Radixact
SUNNYVALE, Calif. , Sept. 20, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data and first-hand experience with its advanced CyberKnife® and Radixact™ Systems , and unique software solutions, will be shared by leading radiation oncology practitioners at the 2017
First Study to Evaluate the Use of Stereotactic Body Radiation Therapy in Low-Risk Prostate Cancer 10 Years Post Treatment SUNNYVALE, Calif. , Sept. 26, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from a prospective study of 230 men with low-risk prostate
SUNNYVALE, Calif. , Oct. 4, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Stock Market Rules, an equity inducement award to Shig Hamamatsu , the company's new VP, Finance & Chief Accounting Officer. As a material inducement to Mr.
*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.
